Tagged with Insight

Pharma Amgen Netherlands is preparing to launch five new products next year, including their leading cardiovascular biotech product Repatha and recently announced the acquisition of the Dutch biotech Dezima. General manager Jasper van Grunsven explains the challenges of preparing for the upcoming year in the midst of structural changes to the…

Pharma Philippe Luscan reveals how Sanofi contributes almost USD 6.35 billion net to the French economy; how their five new global business units will drive future growth, and why they are now accelerating their investment in biologics. As the national champion in the healthcare sector, what is the importance of Sanofi…

Pharma Christian Deleuze reveals the impact of the acquisition by Sanofi in 2011; explains the profitability and global reach of the bio manufacturing facility in Lyon; and tells us that the current system does not capture the benefits that the next generation of gene therapy products deliver over time, transforming chronic diseases into…

Pharma Novasep is the largest contract manufacturer for the pharmaceuticals and fine chemicals industries in France. Michel Spagnol, the company’s chairman and CEO, highlights recent reorganization and “back to basics” strategy based on organic growth improving the product mix and underscoring new investments. What is your perspective regarding the state of…

Pharma Dr. Giorgio Pisani, President and CEO of IBSA Italy, talks about his founding of the company in 2001 and its rapid growth in the market through a combination of organic growth and acquisitions, as well as the current direction of the IBSA group and his ambitions for the company in…

Pharma Maikel Beerens, CEO and founder of Xilloc, a promising Dutch company that designs patient-specific implants, anatomical models and surgical guides for bone reconstruction or augmentation with the help of 3-D printing, explains how his company aims to provide patients worldwide with the tailor-made implants they deserve while reducing the overall socio-economic cost…

Pharma Michiel van der Veen, CEO of GenKey, a global player in biometric identity management based in Eindhoven, explains how both the healthcare industry and public health schemes could benefit from biometric identities to cut costs and improve funds allocation, and how GenKey aims to become the “Google of digital identity”…

Pharma Menno Kok and Roel Kamerling, Director and CIO of Medical Delta, a life sciences, health & technology innovation cluster around Leiden, Delft and Rotterdam in the West of the Netherlands, explains how this network aims to stimulate economic growth and provide healthcare solutions by developing, transferring and implementing knowledge in…

Pharma Bert de Jong, General Manager Benelux at Genzyme, discusses the solutions Genzyme is offering to patients suffering from rare diseases and MS in the Benelux and how these treatments add value overall to society, as well as the company’s changing role in the Sanofi organization with the addition of the oncology and…

Pharma Roche Netherlands General Manager Bart Vanhauwere explains how the company has managed to foster growth at the Dutch affiliate thanks to its long-term strategic vision and the collaborative approach it has taken with stakeholders, as well as the affiliate’s role as a pioneer in introducing innovative pricing models like pay…

Pharma Erin Gainer, the CEO of HRA Pharma, reveals how the company has significantly grown its business in the fields of women’s health and endocrinology over the past decade to become a leading European pharmaceutical company with a global product presence and local operations in 11 European countries. She goes on…

Pharma Pascal Brossard, the Managing Director of Zambon France and President of Afipa (Association for the French self-medication medicines industry), reveals why he is confident that the self-medication market in France will witness substantial growth in the years ahead; and how as a family-run Italian company Zambon has a long-term vision,…